Sarcoidosis — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
ACE I/D genotype influences longitudinal serum ACE activity in sarcoidosis.
Leffers Henrik Christian Bidstrup et al. — Gene (5 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41871628/
- 2.
The double threat: imaging manifestations of thoracic sarcoidosis with miliary nodules and myocardial involvement with radiologic-pathologic correlation.
Kataria Shweta et al. — The international journal of cardiovascular imaging (4 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41933232/
- 3.
Double-QRS Complex Revealing a Multilayer Intramural-Epicardial Ventricular Tachycardia Circuit in Cardiac Sarcoidosis.
Takahashi Masao et al. — JACC. Case reports (3 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41931096/
- 4.
[Bone sarcoidosis: an underrecognized manifestation of a multisystemic disease].
Beniada Camille et al. — Revue medicale suisse (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41923513/
- 5.
Remission in sarcoid uveitis: identification of predictive factors.
Siriphanh Amy et al. — The British journal of ophthalmology (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41922096/
Clinical Trials — Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia
Active (not recruiting) — Na — Western Sydney Local Health District
https://clinicaltrials.gov/study/NCT05524077
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Sarcoidosis
Sarcoidosis is a chronic inflammatory disease characterised by the formation of granulomas that can affect any organ but most commonly the lungs and lymph nodes. Its cause remains unknown. Many patients experience spontaneous remission, but a significant minority develop progressive organ damage requiring long-term treatment.
Most Recent Research
PURPOSE: Serum angiotensin-converting enzyme (sACE) is widely used as a biomarker in sarcoidosis, yet interpretation is complicated by genetic variability. We investigated whether ACE insertion/deletion (I/D) genotype influences longitudinal sACE activity and its relationship to clinical manifestations and treatment response. METHODS: Forty-six patients with confirmed sarcoidosis and available ACE genotype data were included. sACE activity was measured longitudinally and normalized to the assay-specific upper limit of normal (sACE index). Linear mixed modeling assessed genotype-specific trajectories over time. Organ involvement and treatment response were compared across genotypes. RESULTS: Genotype distribution was DD (35%), ID (41%), and II (24%). Baseline sACE index showed a descending numerical trend across genotypes but did not differ significantly. Longitudinal modeling demonstrated a significantly steeper decline in sACE index in DD compared with ID and II genotypes (p < 0.001 for interaction). Organ involvement and treatment response did not differ across genotypes. CONCLUSION: ACE I/D genotype influences longitudinal serum ACE activity in sarcoidosis. Genotype-informed interpretation may improve biomarker-based monitoring.
Common Questions
What is Sarcoidosis?
Sarcoidosis is a chronic inflammatory disease characterised by the formation of granulomas that can affect any organ but most commonly the lungs and lymph nodes. Its cause remains unknown. Many patients experience spontaneous remission, but a significant minority develop progressive organ damage requiring long-term treatment.
How many clinical trials are available for Sarcoidosis?
RareWays currently indexes 218 clinical trials for Sarcoidosis, of which 49 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Sarcoidosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Sarcoidosis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.